Shantelle Kuria/LinkedIn
Nov 27, 2025, 04:58
Shantelle Kuria – von Willebrand Disease: Complex Protein, Difficult Market
Shantelle Kuria, Master of Science in Molecular Medicine at Imperial College London, posted on LinkedIn:
”Ever cut your finger while cooking… and watched it bleed for a moment before it just… stops?
That tiny, almost forgettable moment is driven by a proetin most people have never heard of: von Willebrand factor (VWF).
A few weeks ago, I was exploring VWF biology in an MSc lecture, at the very same time, I was supporting an early-phase clinical trial in VWD in my CRO role.
Two worlds…academic and operational…aligning around the same protein.
And it made me ask:
- What actually drives innovation in bleeding disorders?
- And why is a rare disease like VWD suddenly gaining strategic momentum across industry?
In the full piece, I unpack:
- Science – why VWF’s chaotic multimer structure matters.
- Early-Phase Reality – why VWD trials are some of the hardest to run.
- Market Shift – how recombinant and engineered designs are reshaping a quiet market.
- IP and Strategy – how manufacturing patents + orphan exclusivity shape who can compete.
Full article here.
(Would love to hear your take on it.)”
Stay updated with Hemostasis Today.
-
Jan 14, 2026, 11:38Khokon Miah Akanda Shares A major 4-Guideline Comparison on BP Management in Stroke
-
Jan 14, 2026, 11:26Pablo Albasanz-García and Colleagues on Anticancer Treatment-Induced Arterial and Venous Thrombosis
-
Jan 14, 2026, 11:16ISTH 2026: Laurent Bertoletti To Serve as Vice Theme Leader for VTE
-
Jan 14, 2026, 11:08Leni von Bonsdorff Invites You to Hear and Learn The Latest News in The Plasma Field
-
Jan 14, 2026, 05:56Arun V J on The “Whole Blood” Nostalgia Trap
-
Jan 13, 2026, 16:38Caitlin Raymond: Understanding TAMOF as a TTP-Like Process
-
Jan 13, 2026, 15:22John Amako: Childhood to Adulthood Management Approach for SCD
-
Jan 13, 2026, 13:03Claudio Laudani on Dual Versus Single Antiplatelet Therapy
-
Jan 13, 2026, 12:46Stephanie Carlin and Colleagues on Clinical Outcomes of DOAC-Anticonvulsant Coprescription